METASTATIC PROSTATE ADENOCARCINOMA
Clinical trials for METASTATIC PROSTATE ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radiation approach aims to tame recurrent prostate cancer with fewer side effects
Disease control OngoingThis study tests two types of radiation therapy—proton beam and IMRT—given in shorter courses for men whose prostate cancer has come back and spread only to pelvic or abdominal lymph nodes. The goal is to see if the shorter treatment is safer and causes fewer severe side effects.…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 07:52 UTC
-
New combo aims to boost immune attack on Hard-to-Treat prostate cancer
Disease control TerminatedThis study tests whether combining two drugs, vidutolimod and nivolumab, can help the immune system find and destroy prostate cancer cells that have spread. It is for men whose cancer has stopped responding to standard hormone therapy and chemotherapy. The goal is to see if this …
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 07:51 UTC
-
Promising combo targets tough prostate cancer in bones
Disease control OngoingThis study is for men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. It tests two drugs together: olaparib, which stops cancer cells from repairing themselves, and radium-223, a radioactive drug that targets bone tu…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
New combo therapy shows promise for returning prostate cancer
Disease control OngoingThis study tests a combination of hormone therapy (leuprolide, apalutamide, abiraterone) and precise radiation (SBRT) in 28 men whose prostate cancer has returned and spread to a few spots. The goal is to see if this approach can lower PSA levels to nearly undetectable. Participa…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Targeted drug cocktail shows promise for rare prostate cancer mutation
Disease control OngoingThis study tests a two-drug combination (niraparib/abiraterone plus prednisone) in men with a specific genetic change (SPOP mutation) in their advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the drugs can shrink t…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug cocktail shows promise in slowing tough prostate cancer
Disease control OngoingThis study tests whether adding rucaparib to standard enzalutamide treatment helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 participants will receive either the combination or enzalutamide alone. The goal is to see if t…
Matched conditions: METASTATIC PROSTATE ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 20, 2026 11:54 UTC